The correlation of regression in primary melanoma with sentinel lymph node status

Journal of Clinical Pathology

Volumn 61, Issue 3, 2008, Pages 297-300

  Kaur, C ^a   Thomas, R J ^a   Desai, N ^b   Green, M A ^a   Lovell, D ^c   Powell, B W E M ^b   Cook, M G ^a,c  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Postgraduate Medical School   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SIZE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MELANOMA; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; STATISTICAL SIGNIFICANCE;

FIBROSIS; FOLLOW-UP STUDIES; HUMANS; LIKELIHOOD FUNCTIONS; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM REGRESSION, SPONTANEOUS; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 40449131465     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.049411     Document Type: Article

References (30)

1. Liszkay G, Orosz Z, Peley G, et al. Relationship between sentinel lymph node status and regression of primary malignant melanoma. Melanoma Res 2005;15:509-13.
2. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma. Cancer 1978;42:2282-92.
3. Menzies SW, McCarthy WH. Complete regression of primary cutaneous malignant melanoma. Arch Surg 1997;132:553-6.
4. King M, Spooner D, Rowlands DC. Spontaneous regression of metastatic malignant melanoma of the parotid gland and neck lymph nodes: a case report and a review of literature. Clin Oncol 2001;13:466-9.
5. Trau H, Rigel DS, Harris MN, et al. Metastases of thin melanomas. Cancer 1983;51:553-6.
6. Shaw HM, Rivers JK, McCarthy SW, et al. Cutaneous melanomas exhibiting unusual biologic behaviour. World J Surg 1992;16:196- 202.
7. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. Cancer 1985;56:2287-91.
8. Naruns PL, Nizze JA, Cochran AJ, et al. Recurrence potential of thin primary melanomas. Cancer 1986;57:545-8.
9. Slingluff CL, Voumer RT, Reintgen DS, et al. Lethal thin malignant melanoma: identifying patients at risk. Ann Surg 1988;208:150-61.
10. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous melanomas clinical stage I. A study of 486 cases. Virchows Archiv A Pathol Anat Histopathol 1985;408:241-7.
11. Elder DE, Murphy GF. Melanocyte tumours of the skin. Armed Forces Institute of Pathology, 1991:163-4.
12. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002;138:603-8.
13. Cook MG, Spatz A, Brocker EB, et al. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of EORTC melanoma group. J Pathol 2002;197:188-93.
14. Kelly M, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001;130:151-6.
15. Shaw HM, McCarthy SW, McCarthy WH, et al. Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 1989;15:257-65.
16. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
17. Mackie RM, Byrne D, Lyngam MK, et al. Prognostic evaluation of sentinel node biopsy. Melanoma Res 1992;7:S102.
18. Cook MG. The significance of inflammation and regression in melanoma. Virchows Archiv A Pathol Anat 1992;420:113-15.
19. Balch CM, Soong S, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee or Cancer Melanoma Staging System. J Clin Oncol 2001;19:3622-34.
20. Wagner JD, Jaimie Ranieri, David Z, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenopathy for melanoma. Plastic and Reconstructive Surgery 2003;112:486-97.
21. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-17.
22. Fontaine D, Parkhill W, Greer W, et al. Partial regression of primary cutaneous melanoma. Is there an association with subclinical sentinel lymph node metastasis. Am J Dermpath 2003;25:371-6.
23. Cook MG, Green MA, Anderson B, et al. The development of optimal path of assessment of sentinel lymph node for melanoma. J Pathol 2003;200:314-19.
24. Balch CM, Buzard AC, Soong SJ, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
25. Perrott RE, Glam LF, Reintgen DS, et al. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in management of cutaneous malignant melanoma. J Am Acad Dermatol 2003;49:567-88.
26. Breslow A. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
27. Van Der Esch EP, Cascinelli N, Preda F, et al. Stage I melanoma of skin; evaluation of prognosis according to histologic characteristics. Cancer 1981;48:1668-73.
28. Blessing K, McLaren KM, Waston AC. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990;17:389-95.
29. Paladugu RR, Yonemoto RH. Biologic behaviour of thin malignant melanomas with regressive changes. Arch Surg 1983;118:41-4.
30. Park KG, Blessing K, McLaren KM, et al. A study of thin (<1.5 mm) malignant melanomas with poor prognosis. Br J Plast Surg 1993;46:607-10.